Lancet study of 10166 chronic Hepatitis C patients shows treatment with direct-acting antivirals was associated with a 52% decrease in all-cause mortality (adjusted HR 0·48) and a 34% decrease in hepatocellular carcinoma (0·66) https://t.co/62HylUMUwE